Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Iressa gefitinib: Phase II data; marketed

Follow-up data from the Phase II IDEAL 2 study in

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE